

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **ESSEX BIO-TECHNOLOGY LIMITED**

**億勝生物科技有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 1061)**

### **PROFIT WARNING**

This announcement is made by Essex Bio-Technology Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors of the Company (the “**Board**”) wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on the preliminary review by the Board of the unaudited consolidated management accounts of the Group for the year ended 31 December 2022, the Group expects a decrease in revenue and profit by approximately 20% and 35%, respectively, as compared to the revenue of the Group in the amount of approximately HK\$1,637.7 million and the profit of approximately HK\$346.0 million for the corresponding period in 2021.

The decrease in revenue and profit is primarily attributable to the surge of novel coronavirus (COVID-19) infected cases particularly in the second half of 2022 in a number of provinces and municipalities in the People’s Republic of China (the “**PRC**”), which significantly disrupted the clinical operations of hospitals in the PRC and have prevented non-emergency patients from visiting hospitals and outpatient clinics during 2022. As at the date of this announcement, the clinical operations of hospitals and outpatient clinics remained disrupted as there was a widespread of COVID-19 infected cases following the dismantlement of “zero-COVID control measures” in December 2022 by the relevant PRC government authorities.

Despite the foregoing, the Group maintains a healthy cash flow and financial position to meet its business needs. As at the date of this announcement, the Group has cash and cash equivalents of approximately HK\$549 million.

The Group's results and performance for the year ended 31 December 2022 have not been finalised yet and may be affected by the impact of fair value changes in respect of certain assets of the Group. Therefore, the actual results of the Group for the year ended 31 December 2022 may differ from the information contained in this announcement.

The information contained in this announcement is based on the Board's preliminary assessment after reviewing the unaudited consolidated management accounts of the Group for the year ended 31 December 2022 and the information currently available to the management of the Group, which have not been reviewed or audited by the independent auditors and/or the audit committee of the Company. Shareholders and potential investors are advised to refer to the announcement of the Company for the results for the year ended 31 December 2022, which is expected to be published in March 2023 in accordance with the requirements of the Listing Rules.

**Shareholders and potential investors are advised to exercise caution when dealing in the shares of the Company.**

On behalf of the Board  
**Essex Bio-Technology Limited**  
**Ngiam Mia Je Patrick**  
*Chairman*

Hong Kong, 10 January 2023

*Executive directors of the Company as at the date of this announcement are Mr. Ngiam Mia Je Patrick, Mr. Fang Haizhou, Mr. Ngiam Hian Leng Malcolm and Ms. Yau Lai Man. Independent non-executive directors of the Company as at the date of this announcement are Mr. Fung Chi Ying, Mr. Mauffrey Benoit Jean Marie and Ms. Yeow Mee Mooi.*